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Abstract
Objective: Sustained b-adrenergic stimulation is a hallmark of sympathetic hyperactivity in cardiovascular diseases. It is
associated with oxidative stress and altered vasoconstrictor tone. This study investigated the b-adrenoceptor subtype and
the signaling pathways implicated in the vascular effects of b-adrenoceptor overactivation.
Methods and Results: Mice lacking the b1- or b2-adrenoceptor subtype (b1KO, b2KO) and wild-type (WT) were treated with
isoproterenol (ISO, 15 mg.g21.day21, 7 days). ISO significantly enhanced the maximal vasoconstrictor response (Emax) of the
aorta to phenylephrine in WT (+34%) and b1KO mice (+35%) but not in b2KO mice. The nitric oxide synthase (NOS) inhibitor
L-NAME abolished the differences in phenylephrine response between the groups, suggesting that ISO impaired basal NO
availability in the aorta of WT and b1KO mice. Superoxide dismutase (SOD), pertussis toxin (PTx) or PD 98,059 (p-ERK 1/2
inhibitor) incubation reversed the hypercontractility of aortic rings from ISO-treated WT mice; aortic contraction of ISO-
treated b2KO mice was not altered. Immunoblotting revealed increased aortic expression of Gia-3 protein (+50%) and
phosphorylated ERK1/2 (+90%) and decreased eNOS dimer/monomer ratio in ISO-treated WT mice. ISO enhanced the
fluorescence response to dihydroethidium (+100%) in aortas from WT mice, indicating oxidative stress that was normalized
by SOD, PTx and L-NAME. The ISO effects were abolished in b2KO mice.
Conclusions: The b2-adrenoceptor/Gia signaling pathway is implicated in the enhanced vasoconstrictor response and eNOS
uncoupling-mediated oxidative stress due to ISO treatment. Thus, long-term b2-AR activation might results in endothelial
dysfunction.
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Introduction
Activation of the sympathetic system is a common feature in
cardiovascular diseases [1]. Acute b-adrenergic activation exerts
essential physiological control of cardiovascular systems, increasing
cardiac output and inducing vasodilatation. However, overactiva-
tion of b-adrenenoceptor (b-AR) induces cardiomyopathy; ac-
cordingly, b-AR blockade improves left ventricular function and
survival in heart failure patients [2].
The signaling mechanisms associated with b-AR overactivation
have been studied in using isoproterenol (ISO)-treated animals [3].
It was demonstrated that ISO treatment induces myocardial
oxidative stress [4] and synthesis of proinflammatory cytokines
[5,6]; these mechanisms were also involved in long-term b-AR
stimulation-induced cardiac damage, such as cardiac hypertrophy,
necrosis and fibrosis. Despite increasing evidence demonstrating
the effects of ISO treatment on the heart, little is known about its
effects on the vasculature. We previously demonstrated that ISO
treatment increased superoxide anion production in the rat aorta,
increasing the vasoconstrictor response to the a1-adrenoceptor
agonist phenylephrine [7,8]. Oxidative stress associated with
altered vascular reactivity was also found in the cerebral arteries of
ISO-treated rats, where it mediated cerebrovascular damage [9].
However, the signaling pathway associated with vascular oxidative
stress induced by b-AR overactivation has not been elucidated.
Cardiac hypertrophy was shown to be induced by ISO via b1-
AR signaling [10,11]. Accordingly, it was demonstrated that ISO
induced oxidative stress via b1-AR by reducing CuZn-SOD
expression in rat myocardium [12]. However, the role of b2-AR in
the pathophysiology of this model remains unclear. ISO infusion
in b2-AR knockout mice enhanced the mortality rate and induced
more apoptosis in the heart, suggesting a protective role of b2-AR
[11]. In contrast, prolonged use of b2-AR agonists was detrimental
in both animals and humans [13,14]. According, mice overex-
pressing b2-AR showed cardiac inflammation and failure,
associated with NADPH oxidase-induced oxidative stress [15].
In blood vessels, early stimulation of b1-, b2- and b3-AR, in lesser
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or bigger extension, can induce vasodilatation [16,17]. Although,
ISO-induced b-AR overactivation leads to oxidative stress and
high vascular contractility [8]. It was shown that the b2-AR might
signal by both Gs and Gi a-subunit protein stimulating different
signaling cellular pathways [18]. However, the individual role of b-
AR subtypes underlying the vascular effects of b-AR over-
activation has not been investigated. Therefore, the aim of this
study was to investigate the b-AR subtype(s) involved in the
vascular effects induced by ISO treatment, as well as the
mechanisms underlying these alterations.
Materials and Methods
This investigation was approved by the Ethical Committee for
Animal Research of the Institute of Biomedical Sciences of the
University of Sao Paulo (permit number: 82/2) and it conforms
with the guidelines for ethical conduct in the care and use of
animals established by the Brazilian Society of Laboratory Animal
Science (SBCAL/COBEA).
Mice
Male mice (4 month-old) lacking functional b1- or b2-ARs and
congenic C57BL/6J or FVB/N background strains were used in
this study [19,20]. Animals were maintained on a 12/12 h light/
dark cycle in a temperature-controlled environment (23uC) with
free access to standard laboratory chow and tap water. Knockout
(KO) and wild-type (WT) mice were randomly treated daily with
ISO (15 mg.g21.day21, sc, suspended in 50 mL soy bean oil) or
vehicle for 7 days. At the end of the treatment, animals were killed
by decapitation and heart and aorta were carefully removed and
processed according to the desired experiments. The ratio of the
left ventricle weight to tibia length was used as an index of
ventricular hypertrophy and confirmed the efficacy of ISO
treatment in WT mice.
Vascular reactivity study
Cylindrical segments (rings) of the thoracic aorta (2 mm in
length), free of connective tissue, were mounted in an isolated
tissue chamber containing Krebs-Henseleit solution (in mM: 118
NaCl, 4.7 KCl, 25 NaHCO3, 2.5 CaCl2-2H2O, 1.2 KH2PO4, 1.2
MgSO4-7H2O, 11 glucose, and 0.01 EDTA) gassed with 95% O2
and 5% CO2. Rings were maintained at a resting tension of 0.5 g
at 37uC at pH 7.4 as previously described [21]. Isometric tension
was recorded using an isometric force transducer (Letica TRI 210,
Spain) connected to an acquisition system (MP100, BiopacSys-
tems, USA).
After a 60 min equilibration period, aortic rings were exposed
to 125 mM KCl to assess the maximal tension. Endothelial
integrity was tested by acetylcholine-induced relaxation (10 mM,
Sigma-Aldrich, Germany) in aortic rings that were contracted with
phenylephrine (,0.1 mM, Sigma-Aldrich). A relaxation response
to acetylcholine larger than 50% was considered to demonstrate
functional integrity of the endothelium. After a washout period,
concentration-response curves to the a1-adrenoceptor agonist
phenylephrine (0.1 nM–10 mM) were obtained.
To evaluate the role of NO and superoxide anion in the
vasoconstrictor response to phenylephrine, some aortic rings were
pre-incubated for 30 minutes with the nonselective nitric oxide
synthase (NOS) inhibitor N-nitro-L-arginine methyl ester (L-
NAME, 100 mM, Sigma-Aldrich) or with superoxide dismutase
(SOD, 150 U/mL, bovine erythrocyte, Sigma-Aldrich). In addi-
tion, some aortic rings from WT and b2KO were incubated for
1 h with pertussis toxin to inactivate Gia protein (PTx, 0.5 mg/
mL, Sigma-Aldrich) [22,23] or for 30 min with MEK (MAPKK)
inhibitor PD 98,059 (1 mM, Sigma-Aldrich), to inhibit phosphor-
ylation of ERK1/2 [24] before the concentration-response curves
to phenylephrine were assessed. Time controls for each drug pre-
incubation were performed. Vasoconstrictor responses to phenyl-
ephrine were expressed as a percentage of the contraction
produced by 125 mM KCl.
Our results demonstrated that the changes induced by ISO
treatment on ventricular morphometry and vascular function did
not differ between C57BL/6J and FVB/N strains (data not
shown). Thus, in the present study we used the inbred FVB/N
strain as the wild-type mice.
Western blot analysis
Total protein extract was obtained from isolated aortas
homogenized in cold RIPA lysis buffer (Amersham, N.J., USA)
containing PMSF (1 mM) and Na3VO4 (1 mM). The homoge-
nates were centrifuged (1,500 g for 20 min at 4uC) and the
supernatants were isolated. The microsomal fraction of aortic
tissue was obtained from a pool of three aortas homogenized in
ice-cold sucrose-Tris-EDTA buffer (Tris 50 mM, sucrose
250 mM, and EDTA 1.0 mM, pH = 7.4). The initial centrifuga-
tion was 10,000 g for 10 min at 4uC, and then the supernatant was
centrifuged at 100,000 g for 60 min. The pellet representing the
microsomal fraction was resuspended in Tris-EDTA. To investi-
gate eNOS dimer:monomer ratio, aortas were lysed in buffer
(50 mmol/L Tris-HCl pH = 8.0; 0.2% Nonidet P-40; 180 mmol/
L NaCl; 0.5 mmol/L EDTA; 25 mmol/L phenylmethylsulphonyl
fluoride; 0.1 mmol/L dithiothreitol; and protease inhibitors). The
protein extracts were quantified in each sample using a BCA
Protein Assay Kit (Thermo Fisher Scientific Inc., Mass., USA).
Total and microsomal protein extract (40 mg and 15 mg,
respectively) were electrophoretically separated by 10% SDS-
PAGE. To analyse eNOS dimerization, non-boiled samples
(40 mg) were resolved by 6% SDS-PAGE at 4uC [25]. Then,
proteins were transferred to polyvinylidene difluoride membranes
(Amersham, USA) overnight at 4uC. The transfer used a Mini
Trans-Blot Cell system (Bio-Rad, USA) containing 25 mmol/L
Tris, 190 mmol/L glycine, 20% methanol, and 0.05% SDS as
previously described [21]. After blockade of nonspecific sites with
5% nonfat dry milk, membranes containing total protein extract
were incubated overnight at 4uC with the following primary
antibodies: anti-Gia-1,2 protein (1:2,000; Upstate, USA), anti-
Gia-3 protein (1:2,000; Upstate), anti-ERK 1/2 (1:1,000, Cell
Signaling), anti-phospho (Thr202/Tyr204)-ERK1/2 (Cell Signal-
ing; 1:1,000), anti-p38 MAPK (1:1,000, Cell Signaling), anti-
phospho (Thr180/Tyr182)-p38 MAPK (Cell Signaling; 1:1,000),
anti-a-actin antibody (1:3,000, Sigma-Aldrich). Membranes con-
taining non-boiled samples were incubated with anti-eNOS
(1:1,000, BD Transduction Laboratories, USA). The protein
content of a-actin was used as an internal control. Membranes
containing proteins from the microsomal fraction were incubated
overnight with primary antibodies against b1-, b2- and b3-
adrenoceptors (1:500; Santa Cruz Biotechnology). Reversible
Ponceau staining (1%, Amresco) was used to check equal loading
of microsomal fraction gels.
After washing (10 mM Tris, 100 mM NaCl, and 0.1% Tween
20), membranes were incubated for 2 hours with a peroxidase-
conjugated IgG antibody according to each primary antibody
used. Immunocomplexes were detected using an enhanced
horseradish peroxidase-luminol chemiluminescence system (ECL
Prime, GE Healthcare) and subjected to autoradiography
(Hyperfilm ECL, Amersham). Signals on the immunoblot were
quantified with ImageJ software (NIH, USA).
b2-Adrenoceptor/Gi Pathway in Vascular Dysfunction
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Reactive oxygen species (ROS) generation
The oxidative fluorescent dye hydroethidine was used to
evaluate the in situ production of ROS [8,21]. Briefly, transverse
aortic sections (10 mm) obtained in a cryostat were incubated at
37uC for 10 min with phosphate buffer. Fresh buffer containing
hydroethidine (5 mM) was topically applied to each tissue section
and the slides were incubated in a light-protected, humidified
chamber at 37uC for 30 min. Some aortic slices were incubated
with phosphate buffer containing apocynin (30 mM, 30 min),
PEG-SOD (150 U/mL, 30 min), L-NAME (100 mM, 30 min),
PTx (0.5 mg/mL, 1 hour) or vehicle (deionized water; time
controls). Negative control sections received the same volume of
phosphate buffer without hydroethidine. Images were obtained
with an optical microscope (Eclipse 80i, Nikon, Japan) equipped
with a rhodamine filter and camera (DS-U3, Nikon, Japan) using a
206 objective.
Statistical analysis
Results were expressed as the mean 6 SEM, and N represented
the number of mice used in each set of experiments. Differences in
the area under the concentration-response curves (AUC) in the
absence (control) and presence of PTx or PD 98,059 were
calculated using GraphPad Prism program. The differences were
expressed as a percentage of the AUC of the corresponding
control treatment.
Data were analyzed by a 2-way ANOVA followed by
Bonferroni post-hoc correction or Student’s t-test using the
GraphPad Prism. Differences between groups were considered
significant at P,0.05.
Results
ISO treatment for 7 days induced a significant increase in the
weight of the left ventricle of wild-type (WT) mice (,24%) and b2-
AR knockout mice (,28%). No increase was observed in b1-AR
knockout mice. This result was in line with previous studies and
confirmed the ability of ISO to induce cardiac hypertrophy via b1-
AR activation [11].
b2-AR mediates the increased vascular reactivity to
phenylephrine induced by ISO treatment
The contractile response induced by KCl (125 mM) was not
modified by ISO treatment in WT (WT: 0.5360.03 g vs. WT/
ISO: 0.6060.04 g, p.0.05; t-test), b1-AR knockout mice (b1KO:
0.5260.03 g vs. b1KO/ISO: 0.5960.04 g, p.0.05; t-test) or b2-
AR knockout mice (b2KO: 0.5960.03 g vs. b2KO/ISO:
0.6860.04 g, p.0.05; t-test). ISO treatment for 7 days enhanced
the phenylephrine-induced vasoconstrictor response in the aortas
of WT mice (Figure 1A); the maximal contractile effect (Emax) was
increased by 33% (WT: 108.364.4% vs. WT/ISO: 144.866.0%
to KCl 125 mM, p,0.0001; t-test) without significant changes in
potency. Similar results were observed in the aortas of b1KO mice
(Figure 1B); ISO increased the Emax by 36% (b1KO:
111.865.0% vs. b1KO/ISO: 153.268.9% to KCl 125 mM,
p,0.0001; t-test). However, a lack of functional b2-ARs prevented
the changes caused by ISO in phenylephrine-induced contraction,
and no differences in the Emax were observed between untreated
and ISO-treated groups (Figure 1C).
Lack of functional b2-AR prevents ISO-induced NO impair
and high superoxide anion production in aorta
Incubation with L-NAME potentiated the phenylephrine-
induced contraction in aortas from all groups evaluated
(Figure 2). In aortas from WT and b1KO mice, L-NAME
increased the Emax to phenylephrine by 56 and 63%, respectively
(Figure 2A and 2B), and in aortas from ISO-treated WT and
b1KO mice, L-NAME increased this contractile response by only
24 and 20%, respectively (Figures 2D and 2E). There was a
reduction in the magnitude of the L-NAME effect in ISO-treated
WT and b1KO mice (L-NAME vs. basal: p,0.05, 2-way
ANOVA; Figures 2D and 2E) in comparison to non-treated WT
and b1KO groups (L-NAME vs. basal: p,0.001, 2-way ANOVA;
Figures 2A and 2B). SOD did not modify phenylephrine
contraction in untreated WT and b1KO mice (Figures 2A and
2B), but significantly reduced this response in aortas from WT and
b1KO mice treated with ISO (p,0.01, 2-way ANOVA;
Figures 2D and 2E), reversing the increase in phenylephrine
contraction induced by ISO (Figures 2A and 2B). Thus, the effects
of ISO on vascular reactivity to phenylephrine were very similar
between WT and b1KO aortas, as well the effects of L-NAME and
SOD incubation.
Previous data from our group demonstrated that knockout of
b2-AR affected the phenylephrine response in aortic rings [21]. In
line with this, we observed that the increase in phenylephrine
response induced by L-NAME in aortas from untreated b2KO was
significant (L-NAME vs. basal: p,0.05, 2-way ANOVA), but in
minor magnitude then WT (Figure 2A and 2C); and SOD reduced
the contractile response to phenylephrine in this vessel without
changes the in Emax (Figure 2C). The treatment of b2KO mice
with ISO did not change the magnitude of the effects of L-NAME
or SOD compared with non-treated b2KO mice (Figures 2C and
2F).
Together, these results reinforce our previous studies [7,8,26],
suggesting that ISO treatment induces changes in vascular
reactivity to phenylephrine that are associated with oxidative
stress. Furthermore, we add new data that these adjustments seem
to be dependent of the presence of functional vascular b2-AR.
Expression of b-AR subtypes is not affected by ISO
treatment
The membrane fraction of aortas from WT animals expressed
both b1- and b2-ARs, while the b3-AR subtype was not detected
(Figure 3A, 3B and 3C). As expected, no significant staining for the
b2-AR subtype was observed in aortas of b2KO mice, and b1-AR
was not detected in aortas of b1KO mice (Figure 3A, 3B and 3C).
ISO treatment did not modify the expression of the b1- or b2-AR
in any group, and the b3-AR protein expression remained
undetected (Figure 3A, 3B and 3C).
ISO treatment enhanced Gia-3 protein expression and
ERK1/2 phosphorylation, whereas reduced eNOS
dimerization in aortas from WT but not b2KO mice
ISO treatment significantly enhanced the expression of Gia-3
protein in aortas from WT but not b2KO mice (Figure 4B). No
changes in Gia-1 or -2 protein levels were found among the groups
(Figure 4A). The total protein expression of ERK 1/2 and p38
MAPK was not modified by the lack of b2-AR or by ISO
treatment. However, ISO enhanced the phosphorylation of ERK
1/2 at residues Thr202/Tyr204 (Figure 4C) but did not alter the
phosphorylation of p38 MAPK (Figure 4D). We further investi-
gated whether eNOS protein dimerization was altered by b-AR
overactivation. After ISO treatment, the ratio of eNOS dimer to
monomer was significantly lower in aortas from WT mice;
whereas the ISO effect was prevented in b2KO mice (Figure 4E).
It was related to a reduction of 62% in the abundance of the
b2-Adrenoceptor/Gi Pathway in Vascular Dysfunction
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dimeric active form of eNOS in WT ISO group compared with
non-treated WT, that not occur in b2KO mice.
Implication of b2-AR/Gia signaling on vascular oxidative
stress and increased response to phenylephrine
following ISO treatment
Inhibiting Gia protein activity with the pertussis toxin or
ERK1/2 phosphorylation with PD 98,059 abolished the increased
contraction to phenylephrine in ISO-treated WT mice, reducing
the response to control WT levels (Figure 5A and 5D,
respectively). Despite these effects on aortas from ISO-treated
WT mice, pertussis toxin or PD 98,059 did not change the
phenylephrine contraction in non-treated WT (Figure 5A and 5D)
or in b2KO mice regardless of ISO treatment (Figure 5B and 5E).
The difference in AUC of the concentration-response curves to
phenylephrine evaluated in the presence and absence of pertussis
toxin (Figure 5C) and PD 98,059 (Figure 5F) revealed significant
participation of Gia protein and p-ERK1/2 pathway in the
phenylephrine response of aorta from ISO-treated WT mice, but
not in b2KO.
Reactive oxygen species production was evaluated in situ by
quantification of hydroethidine fluorescence emission. Basal
oxidative stress was observed in aortic slices from ISO-treated
WT mice compared to control WT mice (Figure 6A and 6B). A
minor but significant enhancement of hydroethidine fluorescence
was observed in b2KO mice, and this fluorescence was not
modified by ISO treatment. Incubation with L-NAME or pertussis
toxin significantly reduced the fluorescence to hydroethidine only
in ISO-treated WT aortas, normalizing the oxidative stress in this
group (Figure 6A and 6B). In contrast, incubation with apocynin
reduced the reactive oxygen species only in b2KO mice; this was
true for both ISO-treated and untreated b2KO mice (Figure 6A
and 6B). SOD incubation significantly reduced the fluorescence to
hydroethidine, abolishing the differences between all groups
studied (Figure 6A and 6B).
Discussion
Sustained sympathetic activation leads to myocardial hypertro-
phy, which is considered a hallmark of b-AR overstimulation. This
precedes heart failure, highlighting the clinical relevance of the
sympathetic system. In addition, sustained sympathetic activation
in cardiovascular disease is characterized by elevated baseline
vascular tone and impaired NO bioavailability [27,28]. However,
the mechanism that leads to these alterations in the vasculature
remains unclear. In the present study, we show that the b2-AR
subtype mediates ISO-induced changes in vascular tone via the
coupled Gia pathway. This effect was associated with sustained b2-
AR activation uncoupling NOS that enhances superoxide anion
generation and thereby decreases NO bioavailability.
It is known that acute activation of b-ARs can directly induce
vasodilatation in smooth muscle cells via a Gs protein/adenylyl
cyclase/cAMP pathway. However, little is known about the
mechanisms associated with the effects of long-term b-AR
activation in vascular cells. Previous studies suggested that ISO-
induced b-AR overactivation leads to alterations in vascular tone
depending on the vessel type [8,9,26,29,30]. In murine aortas,
ISO treatment enhances the contractile response to the a1-
adrenoceptor agonist phenylephrine and is associated with
elevated ROS generation and impaired NO bioavailability
[8,30]. In this study, we determined the b-AR subtype as well as
the downstream mechanisms involved in this effect.
We observed that ISO treatment enhanced the phenylephrine-
induced contraction in aortas from both WT and b1KO mice.
However, this effect was not observed in b2KO mice. These data
suggest that the hypercontractile aortic phenotype induced by
sustained b-AR activation is mediated via the b2-AR. Noteworthy,
the aorta from b2KO mice presented increased contraction to
phenylephrine before ISO treatment. Although the contractility is
increased in these vessels, L-NAME incubation significantly
increased the phenylephrine-induced contraction ISO- and
vehicle-treated b2KO mice; it suggested that even the contractility
of b2KO mice aorta is higher than in WT, it not reached maximal
contractility capacity and can be responsible to a stimuli and/or
injury that could alter vascular contractility. Previously we
demonstrated that b2-AR deficiency enhances aortic contractility
Figure 1. Knockout of b2-AR prevent increase of phenylephrine contractile response induced by isoproterenol in aorta. 7-day
isoproterenol treatment (ISO) increased the vasoconstrictor response to phenylephrine in isolated thoracic aorta from wild-type (WT) (A) and b1-KO
(B) mice. This effect was abolished in b2-KO mice (C). The contraction response is expressed as a % of the contraction to KCl (125 mM). The number of
animals used in each group is indicated in parenthesis. Values are presented as the mean 6 SEM. Significance was assessed with a 2-way ANOVA:
***p,0.0001 vs. WT; +++p,0.0001 vs. b1KO.
doi:10.1371/journal.pone.0091877.g001
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to phenylephrine associated to NADPH oxidase-derived superox-
ide anion generation [21]. This evidenced the crucial physiological
role of b2-AR in the maintenance of vascular tone and redox
status. On the other hand, the current study revealed that
overstimulation of vascular b2-AR has a pathological effect and
could serve as a mechanism of vascular injury via Gai/MAPK-
dependent signaling pathway. In line with this possible patholog-
ical role of b2-AR when overstimulated in vasculature, a previous
study by Xu Q et al. [15] observed that transgenic mice
overexpressing b2-AR showed enhanced superoxide anion pro-
duction, which activated p38 MAPK and contributed to cardiac
remodeling and failure.
Consistent with the role of overactivated b2-AR in cardiac
oxidative stress, we also observed that the ISO-induced ROS
generation was virtually abolished in aortas from b2KO mice,
indicating that the overactivation of b2-ARs induced vascular
oxidative stress. The vascular oxidative stress induced by ISO
seemed to be related to enhanced superoxide anion levels;
incubation with superoxide dismutase normalized both the
contractile response to phenylephrine and the high fluorescence
to hydroethidine in aortas from ISO-treated WT mice. In
addition, a previous study from our group demonstrated that
SOD content in aortas from ISO-treated rats was enhanced,
which counteracted the elevated superoxide generation induced by
b-AR overactivation [8].
Enhanced production of superoxide anion is involved in the
pathogenesis and complication of many cardiovascular diseases by
reducing NO bioavailability. In addition, peroxynitrite and
hydroxyl radicals are produced; these mechanisms induce
endothelial dysfunction [31,32]. The basal release of NO involved
in the control of vascular tone can be estimated by quantifying the
increase in vascular tone by NOS inhibitors like L-NAME [33].
Therefore, we evaluated the effect of L-NAME incubation on the
vasoconstrictor response to phenylephrine in aortas from WT,
b1KO and b2KO mice treated or untreated with ISO. We
observed that L-NAME incubation showed minor contractile
effect on aortas from ISO-treated WT and b1KO mice compared
to their respective non-treated control groups. These results
suggested that control of vascular tone was impaired by a loss of
aortic NO bioavailability. However, this effect of L-NAME was
Figure 2. Role of superoxide anion and NOS in the vascular effect of isoproterenol treatment. Effect of L-NAME (LN, 100 mM) or
superoxide dismutase (SOD, 150 U/mL) on the concentration-response curves to phenylephrine of vehicle- (open symbols) or 7-day isoproterenol-
treated (ISO, close symbols) aortic rings from wild-type (A, D), b1KO (B, E) and b2KO (C, F) mice. The contraction response is expressed as a % of the
contraction to KCl (125 mM). Values are presented at the mean 6 SEM. E+= intact endothelium. The number of animals used in each group is
indicated in parenthesis. Significance was assessed using a 2-way ANOVA: *p,0.05, **p,0.01 vs. WT E+; +p,0.05, ++p,0.01 vs. b1KO E+; #p,0.05 vs.
b2KO E+.
doi:10.1371/journal.pone.0091877.g002
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not observed in ISO-treated b2KO mice compared with non-
treated mice. In addition, after L-NAME incubation, there were
no significant differences in the phenylephrine-induced contrac-
tion among aortas from all groups evaluated. Together, these data
suggest that the b2-AR subtype mediated the impairment of NO
release and the altered vascular tone that were induced by chronic
ISO treatment; while the b1-AR subtype was not involved. This
effect was not expected as studies have demonstrated that acute
b2-AR activation stimulated NO synthesis in endothelial cells of
various vessel types via eNOS activation [34–36]. However,
overstimulated b2-AR seemed to induce a signaling pathway
distinct from the one involved in acute vasodilatation. Together,
the present data suggest that overactivation of b2-AR evoked
adverse effects on vascular tissue.
The b2-AR couples to both Gs and Gi protein a-subunits,
stimulating distinct signaling pathways [18,37]. Acute activation of
b2-AR in mouse pulmonary endothelial cells induces eNOS-
derived NO production via the Gi-Scr kinase-dependent pathway
Figure 3. Aortic b-AR subtypes expression. Protein expression of b1- b2- and b3-adrenoceptors (AR) evaluated in the membrane fraction of
aortas from WT, b1KO and b2KO mice treated for 7 days with vehicle or isoproterenol (ISO). (A) Representative Western-blot autoradiographs for each
b-AR subtype in membrane preparations of aorta and positive controls (+C: heart for b1-AR; skeletal muscle for b2-AR; adipose tissue for b3-AR).
Densitometric quantification was evaluated for b1- (B) and b2-AR (C) but not for b3-AR, as this subtype was not expressed (n.e.) in the mouse aorta.
The number of samples analyzed (pool of 3 aortas in each sample) is indicated in the bar for each group. Values (mean6 SEM) are expressed the fold-
change in b-AR expression compared to the WT. Significance was assessed using a 2-way ANOVA.
doi:10.1371/journal.pone.0091877.g003
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Figure 4. Isoproterenol treatment induces b2-AR-Gi-ERK1/2 pathway activation and eNOS uncoupling. Protein expression of Gia-1,2 (A),
Gia-3 (B), ERK 1/2 phosphorylated at Thr202 and Tyr204 (C), p38 MAPK phosphorylated at Thr180 and Tyr182 (D) and eNOS protein dimerization (E) in
aortas from control and 7-day isoproterenol-treated (ISO) wild-type (WT) and b2KO mice. The top panels in each graph represent typical Western-blot
autoradiographs. Gia protein expression was normalized to the a-actin content in each sample, and phosphorylated ERK 1/2 and p38 MAPK were
normalized to the total content of ERK 1/2 and p38 MAPK, respectively, and these results were expressed as the fold-change compared to WT aorta.
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[38]. However, it is not known if the b2-AR/Gi pathway is
involved in the vascular effects of sustained b-AR activation.
Three distinct proteins, Gia-1, -2 and -3, have been cloned [39],
and all three isoforms have been implicated in adenylyl cyclase
inhibition [40]. We observed for the first time that ISO treatment
significantly elevated the expression of Gia-3 in the vasculature of
WT mice in a manner dependent on the presence of functional
vascular b2-AR.
The involvement of Gia protein signaling in vascular function
has been studied using pertussis toxin it in vivo and in vitro. Pertussis
toxin ADP-ribosylates the Gi protein a-subunit, which contains a
cystein residue near the carboxy terminus and thus inactivates its
activity [41,42]. Here, both the enhanced response to phenyleph-
rine and the oxidative stress found in aortas from ISO-treated WT
mice were pertussis toxin-sensitive. In contrast, Gi protein
inhibition did not affect aortas from untreated WT mice or
ISO-treated or untreated b2KO mice. These results indicate that
the Gia pathway activated by ISO in the vasculature was
dependent on b2-AR. Previous studies found enhanced levels of
Gia-2 and -3 protein and mRNA in aortas from hypertensive
animals [43,44]. Treatment with pertussis toxin reduced the
contractile response to norepinephrine on conduct arteries of
spontaneously hypertensive rats (SHR). In addition, superoxide
anion production was decreased in the vascular smooth muscle
cells of the SHR rats treated with pertussis toxin [42,45].
Together, these data suggest a potential beneficial effect of
selective inhibition of the b2-AR/Gia signaling pathway in the
vasculature. In particular, b2-AR/Gia inhibition could be of
benefit in cardiovascular diseases characterized by high sympa-
thetic tone, such as essential hypertension and heart failure.
eNOS dimerization was expressed as ratio of dimer:monomer band intensity. The number of animals used in each group is indicated in the bars.
Values are presented as the mean 6 SEM. Significance was assessed using a 2-way ANOVA: *p,0.05 vs. WT.
doi:10.1371/journal.pone.0091877.g004
Figure 5. Inhibition of Gia protein or ERK1/2 activation reversed hypercontractility to phenylephrine induced by b-AR
overactivation in aorta of wild-type, but not in b2KO mice. Effect of pertussis toxin (PTx, 4 mM) and PD98,059 (1 mM) on the
concentration-response curves to phenylephrine in aortic rings of wild-type (WT) (A, D) and b2KO (B, E) mice treated for 7 days with vehicle or
isoproterenol (ISO). The contraction response is expressed as a % of the contraction to KCl (125 mM). Bar graphs show differences in the area under
the concentration-response curve (AUC) in the presence or absence of PTx (C) or PD98,059 (F) in WT and b2KO mice treated or not with ISO. Values
are presented as the mean 6 SEM. The number of animals used in each group is indicated in parenthesis. Significance was assessed using a 2-way
ANOVA: +p,0.05 vs. WT ISO; *p,0.05 vs. WT.
doi:10.1371/journal.pone.0091877.g005
b2-Adrenoceptor/Gi Pathway in Vascular Dysfunction
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e91877
Superoxide anion generation was inhibited by L-NAME only in
aortas from ISO-treated WT, without effect in control WT as well
as in b2KO mice with or without ISO treatment. In line with this
finding, we also observed a relative reduction in the abundance of
the active dimeric form of eNOS in ISO-treated WT. By contrast,
dimerization of eNOS in aortas from b2KO treated or not with
ISO was similar to observed in control WT. It is known that
reduced eNOS dimerization is associated with impaired NO
bioavailability and increased superoxide anion production [46],
and previous reports demonstrated that the superoxide anion
generation by eNOS is inhibitable by L-NAME incubation
[47,48]. Taken together, these results suggest that enhanced
superoxide anion production induced by ISO is derived from
uncoupled eNOS and is dependent on b2-AR. In line with the role
of eNOS uncoupling mediating the vascular effect of b-AR
overactivation, L-arginine incubation reduced the increased
contractile response to phenylephrine in aortic rings from ISO-
treated rats [8]. Similar to the effect observed for L-NAME,
pertussis toxin decreased hydroethidine fluorescence only in aortas
from ISO-treated WT mice, suggesting eNOS uncoupling induced
by b-AR overactivation is associated with Gia protein signaling.
Furthermore, there was no effect of apocynin on the ISO-induced
vascular oxidative stress in aortic mice, which reinforce that
vascular NADPH oxidase was not involved in this effect of ISO.
Of note, lack of b2-AR induced a mild oxidative stress in the aorta
that was reversed by apocynin. This result agreed with a previous
study that reported an antioxidant role of constitutive b2-ARs, in
which inhibition of NADPH oxidase contributed to the mainte-
nance of vascular tone [21]. Conversely, L-NAME or pertussis
toxin did not affect the DHE fluorescence in vessels from b2KO
mice, treated or untreated with ISO. Taken together, these
observations suggested that the b2-AR/Gia pathway leads to
eNOS uncoupling during ISO-induced b-AR overactivation. This
role of b2-AR is in addition to its physiological role inhibiting
Figure 6. Gia protein activity mediates the vascular oxidative stress induced by isoproterenol. Panel A shows representative
fluorographs of microscopic sections of thoracic aorta from wild-type (WT) and b2KO mice treated for 7 days with vehicle or isoproterenol (ISO).
Vessels were labeled with the oxidative dye hydroethidine, which produces a red fluorescence when oxidized to ethidium bromide. Panel B shows
the densitometric analysis of the ethidium-bromide-positive nuclei evaluated under basal conditions or incubated with apocynin (APO, 30 mM), L-
NAME (LN, 100 mM), PTx (4 mM) or superoxide dismutase (SOD, 150 U/mL). The fluorescence signal was evaluated as the intensity of fluorescence per
pixel normalized by vessel area. Values are presented as the mean 6 SEM. N = 4–7 animals in each group. Significance was assessed using a 2-way
ANOVA: *p,0.05 vs. respective basal values for each group; #p,0.05 vs. basal WT value; +p,0.05 vs. ISO-treated WT value.
doi:10.1371/journal.pone.0091877.g006
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NAPDH oxidase. The importance of this mechanism is raised by
the fact that therapeutic interventions that could improve eNOS
uncoupling were proposed to ameliorate endothelial dysfunction
in many cardiovascular diseases associated with b-adrenergic
overstimulation [53].
Gi protein-coupled b2-AR induces the activation of MAPKs
[18]. It was previously demonstrated that long-term ISO
stimulation of b-ARs enhanced phosphorylated ERK 1/2 in the
heart and cerebral arteries. This was concomitant with a time-
dependent reduction in PKA activity [49]. We demonstrated here
that 7-day ISO treatment enhanced phosphorylated (p)-ERK 1/2
in the mouse aorta. This effect was blocked in b2KO mice,
evidence for the first time that b2-AR overstimulation activates
ERK 1/2 in the vasculature. Considering that the activated ERK
1/2 signaling led to eNOS uncoupling [50], the present results
strongly suggested that overstimulation of the b2-AR/Gia/p-ERK
1/2 signaling pathway mediated the oxidative stress and reduced
NO bioavailability induced by ISO treatment. These results
provided a new mechanism underlying superoxide anion gener-
ation from eNOS uncoupling, which may have an important role
in the pathogenesis of endothelial dysfunction in diseases
secondary to sympathetic overactivation [51,52]. Reinforcing this
hypothesis, it was found that the inhibition of p-ERK1/2
normalized the hypercontractility to phenylephrine observed in
aortas from ISO-treated WT mice; whereas this inhibitor did not
show significant effect on the phenylephrine response of aortas
from WT, b2KO and ISO-treated b2KO mice. Thus, these
functional results associated with the increased p-ERK1/2 protein
expression suggest that an up-regulated p-ERK1/2 pathway is
involved in the ISO effect to enhance vascular contractility to
phenylephrine associated with reduced NO bioavailability,
depending on the presence of functional b2-AR.
Sustained adrenergic overstimulation by elevated circulating
catecholamines down regulates b-ARs, reducing the receptor
density on the cell membrane and thus impairing downstream
signaling. Seven day ISO treatment reduces the density of b-ARs,
mainly b2-ARs, in cardiac tissue [54]. However, independent of
changes in the number of b-ARs, the subtype b2-AR may
uncouple from Gsa and couple to Gia protein; these effects are
secondary to phosphorylation of b2-ARs or changes in the
expression of G-protein isoforms [18,55]. Thus, we investigated
if the vascular effects of ISO treatment were associated with a
down regulation of b-ARs in aortic tissue. It was previously shown
that both b1- and b2-ARs were expressed in mouse conduit arteries
[17,21]. In contrast, no evidence of the b3-AR subtype was
observed in these vessels [17,21]. As expected, we found no
expression of the b3-AR subtype in membrane extracts of mouse
aorta, and ISO treatment had no effect. This suggested that the
b3-AR subtype did not mediate the vascular effects of b-AR
overactivation. b1- and b2-ARs were significantly expressed in the
plasma membrane extracts of mouse aorta, but ISO treatment did
not change their density in the membrane extracts from both WT
and knockout mice. Thus, the vascular effects of ISO were not
related to changes in b-AR subtype density; instead, the ISO
effects were likely mediated by b2-AR coupling to up-regulated
Gia protein.
It is known that chronic stimulation of b-AR recruits the
proteins b-arrestins, that together G protein-coupled receptor
kinases (GRKs) lead to desensitization of b-adrenoceptor, facili-
tating receptor internalization and can result in its degradation or
recycling. In addition, b-arrestins and GRKs can play a role as
signaling molecules mediating function other than the desensiti-
zation process. Considering that ISO stimulation of b2-AR can
induce p-ERK in cultured HEK cells via b-arrestin and GRK 5/6
dependent and G protein-independent pathway [56], we cannot
exclude the hypothesis that b-arrestin is involved in the
isoproterenol-induced p-ERK 1/2 in vascular tissue, in addition
to Gi protein pathway. On the other hand, haemodynamic
alterations seems to be not involved in the vascular effect of
chronic ISO administration, as previous report have demonstrated
heart rate and arterial pressure in WT and b2KO treated for
several days with ISO similar to WT group treated with saline
[11,57]. Of note, basal heart rate and arterial pressure in b2KO
without ISO are not different from control WT [11,21].
There is evidence for the potential clinical benefits of b2-AR
signaling inhibition in cardiovascular diseases [58–60]. Impor-
tance of this signaling related to this beneficial effect was not clear
because there is no available specific pharmacological tool to
blockade Gi-coupled b2-AR signaling pathway [61]. Then, the
genetic animal models are very helpful tools to reveal the
functional importance of this signaling.
In conclusion, we propose a pivotal role of the b2-AR/Gia
pathway in mediating the adverse effects of ISO-induced b-AR
overstimulation. Enhanced p-ERK 1/2 and eNOS uncoupling
lead to high superoxide anion production and reduced NO
bioavailability, increasing the contractile response to phenyleph-
rine in the mouse aorta. Prevalent diseases as heart failure and
essential hypertension are particularly prone to vascular injury due
to oxidative stress. In view of the central importance of
sympathetic hyperactivity in these cardiovascular diseases, the
involvement of b2-AR/Gia signaling pathway in adverse vascular
effects provides new insight into therapeutic approach for
improvement of endothelial dysfunction and NO bioavailability.
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